Growth
in this market is driven by the increasing number of ESRD patients, the growing prevalence
of diabetes & hypertension (major causes of kidney failure), preference for
dialysis treatments over kidney transplants due to lack of donors, and
initiatives taken by leading players to introduce advanced products &
services.
The report China Hemodialysis and Peritoneal Dialysis Market is projected to reach USD 7.4 billion by 2024 from USD 5.0 billion in 2019, at a CAGR of 8.5%.
The
China hemodialysis market is broadly categorized into two segments, namely,
hemodialysis products and hemodialysis services market. The hemodialysis (HD)
products market include machines (center-use & home-use machines) &
consumables (dialyzers, access products, bloodlines, dialysates, and other
consumables). The hemodialysis services (including in-center & home-
hemodialysis services) segment is expected to account for the largest share of
the China dialysis market. An increasing number of dialysis centers coupled
with the growing prevalence of ESRD is the major factor driving the growth of
the hemodialysis services market in China.
The peritoneal dialysis market, by modality, includes continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The APD segment is expected to grow at the fastest CAGR owing to its several advantages over CAPD—daytime freedom for patients, fewer connections and disconnections (and hence a lower probability of peritonitis), and improved quality of life. Being automated, APD is preferred for dialysis treatment in the elderly and children.
The
major players operating in the China hemodialysis and peritoneal dialysis
market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter
International, Inc. (US) and Shandong Weigao Group Medical Polymer Company
Limited (China). Other players in this market include B. Braun Melsungen AG
(Germany), Nikkiso Co. Ltd. (Japan), DaVita Healthcare Partners, Inc (US),
Asahi Kasei Medical Co., Ltd (Japan), Bain Medical Equipment Co.,
Ltd. (China), Huaren Pharmaceutical (China), and Jiangsu Lengthen Life
Science and Technology Co. Ltd (China)